Dovato (dolutegravir, lamivudine) and Triumeq (dolutegravir, abacavir, lamivudine) are both indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. In addition, both Dovato and Triumeq contain dolutegravir and lamivudine and should not be taken with any other medicinal products also containing dolutegravir and lamivudine.